Pfizer scrapped its own obesity drug candidate, Danuglipron, in early 2025, citing risks of liver enzyme elevations. ・The ...

Speaking on the sidelines of the J.P. Morgan Healthcare Conference, Novo business development executive Tamara Darsow said ...

Pfizer is gearing up for a consumer-driven obesity drug market, drawing parallels to the demand surge it experienced with the ...

The U.S. Food and Drug Administration approved the Wegovy pill to reduce body weight and maintain weight reduction for a ...

Pfizer is a Buy at low valuation but faces a 2030 patent cliff, COVID sales declines, and LOE risks. Click here to read an ...

Facing the loss of exclusivity on key products, Pfizer has pulled forward its lead obesity asset into Phase III and targeted ...

Pfizer has agreed to acquire weight-loss drugmaker Metsera in a transaction that could exceed $10 billion. Under the terms of the cash deal, Pfizer will pay $65.60 a share upfront, along with a ...

The Delaware Chancery Court denied Pfizer Inc.’s (NYSE:PFE) request for a temporary restraining order to prevent Metsera, Inc. (NASDAQ:MTSR) from terminating the existing merger agreement in favor of ...

Drugmaker CEOs see sales online channels as a budding opportunity, while some biotech investors told BioPharma Dive to expect ...

NEW YORK, Nov. 5, 2025 /PRNewswire/ -- Metsera, Inc. (NASDAQ: MTSR) ("Metsera" or the "Company") today issued the following statement in response to a ruling in the litigation filed against the ...

Despite additional cost savings in 2026, Pfizer also forecasts that its adjusted earnings per share (EPS) will likely decline ...

Metsera was the target of a bidding war by pharma giants. The company has an innovative obesity drug candidate. 10 stocks we like better than Metsera › Innovative biopharmaceutical company Metsera ...